Table 4.
Effect of Apigenin Treatment on OVA-Induced Alterations in Spleen GATA3, T-bet, STAT6, and SOCS1 mRNA Expression in AR Mice.a
| Parameters | Treatment | ||||||
|---|---|---|---|---|---|---|---|
| Normal | AR Control | MLT (10) | AP (5) | AP (10) | AP (20) | Per se | |
| GATA3/β-actin ratio | 1.09 ± 0.08 | 2.07 ± 0.19b | 1.50 ± 0.07c,d | 2.03 ± 0.07 | 1.70 ± 0.13c,d | 1.48 ± 0.11c,d | 1.09 ± 0.12 |
| T-bet/β-actin ratio | 0.89 ± 0.10 | 0.43 ± 0.12b | 0.86 ± 0.06c,d | 0.43 ± 0.09 | 0.71 ± 0.13c,d | 0.78 ± 0.09c,d | 0.90 ± 0.12 |
| p-STAT6/β-actin Ratio | 1.05 ± 0.14 | 2.21 ± 0.09b | 1.32 ± 0.09c,d | 2.07 ± 0.13 | 1.54 ± 0.10c,d | 1.36 ± 0.15c,d | 1.37 ± 0.08 |
| SOCS1/β-actin ratio | 0.44 ± 0.12 | 1.28 ± 0.09b | 0.57 ± 0.09c,d | 1.17 ± 0.10 | 0.88 ± 0.10c,d | 0.64 ± 0.11c,d | 0.51 ± 0.11 |
Abbreviations: ANOVA, analysis of variance; AP (5), apigenin (5 mg/kg) treated; AP (10), apigenin (10 mg/kg) treated; AP (20), apigenin (20 mg/kg) treated; AR, allergic rhinitis; GATA-3, GATA binding protein 3; OVA, ovalbumin; MLT (10), montelukast (10 mg/kg) treated; mRNA, messenger RNA; SEM, standard error of the mean; STAT6, signal transducer and activator of transcription 6; SOCS1, silencing of the suppressor of the cytokine signaling-1; T-bet, T-box protein expressed in T cells. Figures in parentheses indicate a dose in mg/kg.
a Data are represented as mean ± SEM (n = 4-6) and analyzed by one-way ANOVA followed by Tukey multiple range test.
b P < .05 as compared with normal group.
c P < .05 as compared with AR control group.
d P < 0.05 as compared montelukast with apigenin.